Sanofi-Aventis receives European marketing approval for obesity drug

By Lisa Kerner

Charlotte, N.C., June 21 - The European Commission granted marketing authorization to Sanofi-Aventis' CB1 blocker Acomplia (rimonabant 20 mg/day) in all 25 European member states as an adjunct to diet and exercise for the treatment of obese or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaemia.

The authorization was based on efficacy and safety data from a clinical trial of more than 6,600 patients worldwide.

Results showed that one Acomplia 20 mg tablet taken every day significantly decreased weight and waist circumference, HbA1 and triglycerides, while increasing HDL-cholesterol levels.

Paris-based Sanofi-Aventis develops products used in therapeutic areas including cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.